



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stephen R. Hanson  
Serial No. : 10/603,401  
Filed : June 25, 2003  
Conf. No. : 3459  
Title : METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS

Art Unit : 1615  
Examiner : Thurman K. Page  
Cust. No. : 20985

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**


Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Forms PTO-1449 (8 pages), cited non U.S. patent references, and a return postcard for filing in connection with the above-identified application. Because this Supplemental Information Disclosure Statement is filed prior to receipt of a first office action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:



The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

  
Stephanie L. Seidman  
Reg. No. 33,779

**Dated: September 12, 2005**  
Attorney Docket No. 18852-002002/5202B  
**Address all correspondence to:**  
Stephanie L. Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-5070  
Facsimile: (202) 626-7796  
email: seidman@fr.com



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stephen R. Hanson  
Serial No. : 10/603,401  
Filed : June 25, 2003  
Conf. No. : 3459  
Title : METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS

Art Unit : 1615  
Examiner : Thurman K. Page  
Cust. No. : 20985

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**


Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Forms PTO-1449 (8 pages), cited non U.S. patent references, and a return postcard for filing in connection with the above-identified application. Because this Supplemental Information Disclosure Statement is filed prior to receipt of a first office action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:



The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

  
\_\_\_\_\_  
Stephanie Seidman  
Reg. No. 33,779

**Dated: September 12, 2005**  
Attorney Docket No. 18852-002002/5202B  
**Address all correspondence to:**  
Stephanie L. Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-5070  
Facsimile: (202) 626-7796  
email: seidman@fr.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stephen R. Hanson  
Serial No. : 10/603,401  
Filed : June 25, 2003  
Conf. No. : 3459  
Title : METHODS AND COMPOSITIONS FOR TREATING PLATELET-RELATED DISORDERS

Art Unit : 1615  
Examiner : Thurman K. Page  
Cust. No. : 20985

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98**

Because this Supplemental Information Disclosure Statement is filed before the receipt of a First Office Action on the Merits for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (8 pages) and copies of the cited non U.S. Patent documents are provided herewith, via hand delivery.

The documents cited on the Forms PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following pending U.S. Applications that have one or more common inventors and/or are commonly owned:

<u>U.S.S.N.(App. No.)</u>	<u>Filing Date</u>	<u>Docket No.</u>
11/127,544	05/11/05	002003/5202C
10/602,293	06/24/03	—
10/165,442	06/07/02	—


Applicant : Stephen R. Hanson  
Serial No. : 10/603,401  
Filed : June 25, 2003  
Page : 2 of 2

Attorney's Docket No.: 18852-002002/5202B  
Information Disclosure Statement

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and they be made of record in the file history of the above-captioned application.

Respectfully submitted,



---


Stephanie Seidman  
Reg. No. 33,779

**Dated: September 12, 2005**

Attorney Docket No. 18852-002002/5202B

**Address all correspondence to:**

Stephanie L. Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-5070  
Facsimile: (202) 626-7796  
email: seidman@fr.com



Sheet 1 of 8

Substitute Form PTO-1449 (Modified)  <b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
	Applicant Stephen R. Hanson			
	Filing Date June 25, 2003		Group Art Unit 1615	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2002/0119144	08/29/02	Hanson	424	94.63	04/08/02
	AB	2003/0060630	03/27/03	Lang et al.	544	346	04/25/02
	AC	2004/0028729	02/12/04	Shojaei et al.	424	452	04/29/03
	AD	2004/0062800	04/01/04	Burnside et al.	424	468	12/20/01
	AE	2004/0087035	05/06/04	Hanson	436	514	06/24/03
	AF	3,854,480	12/17/74	Zaffaroni	424	514	06/24/03
	AG	4,105,776	08/08/78	Ondetti et al.	514	423	12/22/76
	AH	4,231,938	11/04/80	Monaghan et al.	549	292	06/15/79
	AI	4,302,386	11/24/81	Stevens	530	322	01/16/80
	AJ	4,316,906	02/23/82	Ondetti et al.	514	422	10/31/80
	AK	4,337,201	06/29/82	Petrillo et al.	548	413	12/04/80
	AL	4,344,949	08/17/82	Hoefle et al.	514	307	02/20/81
	AM	4,346,227	08/24/82	Terahava et al.	560	119	06/05/81
	AN	4,374,829	02/22/83	Harris et al.	514	21	07/17/81
	AO	4,410,520	10/18/83	Watthey	514	212.07	07/19/82
	AP	4,444,784	04/24/84	Hoffman et al.	514	460	12/18/80
	AQ	4,452,775	06/05/84	Kent	424	425	12/03/82
	AR	4,508,729	04/02/85	Vincent et al.	514	419	10/02/81
	AS	4,512,924	04/23/85	Attwood et al.	540	500	05/12/83
	AT	4,587,258	05/06/86	Gold et al.	514	412	07/30/84
	AU	4,675,189	06/23/87	Kent et al.	424	490	02/08/85
	AV	4,739,073	04/19/98	Kathawala	548	406	03/04/85
	AW	4,772,684	09/20/88	Brunck et al.	530	316	02/18/88
	AX	4,780,401	10/25/88	Heusser et al.	424	146.1	03/28/85
	AY	4,816,463	03/28/89	Blankley et al.	514	293	04/07/87
	AZ	4,845,079	07/04/89	Luly et al.	514	18	07/11/88
	BA	4,885,292	12/05/89	Ryono et al.	514	18	06/29/89

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))		Applicant Stephen R. Hanson	
		Filing Date June 25, 2003	Group Art Unit 1615

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	BB	4,894,437	01/16/90	Ten Brink	530	328	06/29/87
	BC	4,897,402	01/30/90	Duggan et al.	514	312	06/29/88
	BD	4,904,646	02/27/90	Karnewsky et al.	514	120	04/18/88
	BE	4,906,624	03/06/90	Chucholowski et al.	514	183	08/02/88
	BF	4,906,657	03/06/90	Roth	514	460	12/21/88
	BG	4,920,109	04/24/90	Onishi et al.	514	171	04/18/88
	BH	4,923,861	05/08/90	Picard et al.	514	227.8	02/07/89
	BI	4,929,620	05/29/90	Chucholowski et al.	514	269	06/01/89
	BJ	4,939,143	07/03/90	Regan et al.	514	326	09/25/89
	BK	4,940,727	07/10/90	Inamine et al.	514	450	10/06/88
	BL	4,940,800	07/10/90	Bertolini et al.	548	304.7	07/27/89
	BM	4,946,860	08/07/90	Morris et al.	514	432	11/03/89
	BN	4,946,864	08/07/90	Prugh et al.	514	460	02/01/88
	BO	4,950,675	08/21/90	Chucholowski	514	336	12/21/88
	BP	4,957,940	09/18/90	Roth	514	557	12/21/89
	BQ	4,963,538	10/16/90	Duggan et al.	514	99	03/13/89
	BR	4,968,693	11/06/90	Joshua et al.	514	460	06/09/89
	BS	4,970,231	11/13/90	Lee et al.	514	292	06/09/89
	BT	4,980,283	12/25/90	Huang et al.	435	71.2	06/02/89
	BU	4,992,429	12/12/91	Ullrich et al.	514	129	08/24/89
	BV	4,994,494	02/19/91	Regan et al.	514	569	12/14/89
	BW	4,996,234	02/26/91	Regan et al.	514	563	12/05/89
	BX	4,997,837	03/05/91	Chucholowski et al.	514	256	10/06/89
	BY	5,001,128	03/19/91	Neuenschwander et al.	514	278	12/15/89
	BZ	5,001,144	03/19/91	Regan et al.	514	436	04/17/90
	CA	5,017,716	05/21/91	Karnewsky et al.	556	405	12/01/89
	CB	5,021,453	06/04/91	Joshua et al.	514	510	06/06/90

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))		Applicant Stephen R. Hanson	
		Filing Date June 25, 2003	Group Art Unit 1615

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	CC	5,025,000	06/18/91	Karenewsky et al.	514	80	03/02/90
	CD	5,034,512	07/23/91	Hudspeth et al.	530	330	08/03/88
	CE	5,036,053	07/30/91	Himmelsbach et al.	514	19	03/15/89
	CF	5,036,054	07/30/91	Kalfenbronn et al.	514	19	06/06/08
	CG	5,055,466	10/08/91	Weller et al.	514	235.8	12/14/89
	CH	5,063,207	11/05/91	Doherty et al.	514	18	07/24/89
	CI	5,063,208	11/05/91	Rosenberg et al.	514	19	06/29/90
	CJ	5,064,825	11/12/91	Chakravarty et al.	514	221	05/16/90
	CK	5,064,965	11/12/91	Ocain et al.	546	99	11/16/90
	CL	5,066,643	11/19/91	Abeles et al.	514	18	01/18/90
	CM	5,071,837	12/10/91	Doherty et al.	514	18	11/28/90
	CN	5,073,566	12/17/91	Lifer et al.	514	381	11/30/89
	CO	5,075,109	12/24/91	Tice et al.	424	193.1	03/18/88
	CP	5,075,451	12/24/91	Ocain et al.	548	302.7	11/16/90
	CQ	5,081,127	01/14/92	Carini et al.	514	359	03/26/90
	CR	5,081,136	01/14/92	Bertolini et al.	514	359	12/13/90
	CS	5,085,992	02/04/92	Chen et al.	435	119	02/25/91
	CT	5,089,471	02/18/92	Hanson et al.	514	11	10/01/87
	CU	5,091,378	02/25/92	Karanewsky et al.	514	80	04/18/88
	CV	5,091,386	02/25/92	Kessler et al.	514	277	09/22/89
	CW	5,095,006	03/10/92	Bender et al.	514	19	07/13/90
	CX	5,095,119	03/10/92	Ocain et al.	548	303.1	11/16/90
	CY	5,098,924	03/24/92	Poss	514	397	09/15/89
	CZ	5,098,931	03/24/92	Duggan et al.	514	460	09/24/90
	DA	5,102,911	04/07/92	Lee et al.	514	510	07/06/90
	DB	5,104,869	04/14/92	Albright et al.	514	212.03	10/25/90
	DC	5,106,835	04/21/92	Albright et al.	514	18	06/22/90

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Stephen R. Hanson	
		Filing Date June 25, 2003	Group Art Unit 1615
(37 CFR §1.98(b))			

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	DD	5,112,857	05/12/92	Vickers et al.	514	460	09/04/90
	DE	5,114,937	05/19/92	Hamby et al.	514	238.2	11/28/89
	DF	5,116,835	05/26/92	Ruger et al.	514	218	12/07/89
	DG	5,116,870	05/26/92	Smith et al.	514	548	06/06/90
	DH	5,130,306	07/14/92	Duggan et al.	514	121	06/06/90
	DI	5,132,312	07/21/92	Regan et al.	514	312	11/27/90
	DJ	5,133,974	07/28/92	Paradissis et al.	424	480	01/24/90
	DK	5,135,935	08/04/92	Alberts et al.	514	305	05/17/91
	DL	5,166,171	11/24/92	Jendralla et al.	514	460	04/02/91
	DM	5,182,298	01/26/93	Helms et al.	514	455	03/18/91
	DN	5,196,440	03/23/93	Bertolini et al.	514	339	05/04/90
	DO	5,202,327	04/13/93	Robl	514	256	07/10/91
	DP	5,250,435	10/05/93	Cover et al.	435	256.1	06/04/91
	DQ	5,256,689	10/26/93	Chiang	514	452	10/26/92
	DR	5,260,332	11/09/93	Dufresne	514	452	02/07/92
	DS	5,262,435	11/16/93	Joshua et al.	514	452	02/10/92
	DT	5,273,995	12/28/93	Roth	514	422	02/26/91
	DU	5,276,021	01/04/94	Karanevsky et al.	514	120	12/19/91
	DV	5,283,256	02/01/94	Dufresne et al.	514	452	07/22/92
	DW	5,286,895	02/15/94	Harris et al.	560	60	12/07/92
	DX	5,302,604	04/12/94	Byrne et al.	514	338	10/06/92
	DY	5,317,031	05/31/94	MacConnell et al.	514	452	11/24/92
	DZ	5,356,896	10/18/94	Kabadi et al.	514	256	12/22/92
	EA	5,369,125	11/29/94	Berger et al.	514	452	03/19/93
	EB	5,385,932	01/31/95	Vickers et al.	514	460	02/18/92
	EC	5,407,686	04/18/95	Patel et al.	424	468	01/29/92
	ED	5,474,995	12/12/95	Ducharme et al.	514	241	01/10/94

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))		Applicant Stephen R. Hanson	
		Filing Date June 25, 2003	Group Art Unit 1615

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	EE	5,506,107	04/09/96	Cunningham et al.	435	7.21	09/29/93
	EF	5,521,213	05/28/96	Prasit et al.	514	443	08/29/94
	EG	5,536,752	07/16/96	Ducharme et al.	514	602	05/08/95
	EH	5,543,297	08/06/96	Cromlish et al.	435	25	05/06/73
	EI	5,550,142	08/27/96	Ducharme et al.	514	365	05/08/95
	EJ	5,552,422	09/03/96	Gauthier et al.	514	368	01/11/95
	EK	5,572,944	11/12/96	Slikkers et al.	114	343	05/27/94
	EL	5,604,253	02/18/97	Lau et al.	514	415	05/22/95
	EM	5,604,260	02/18/97	Guay et al.	514	605	11/04/93
	EN	5,622,985	04/22/97	Olukotun et al.	514	423	04/19/95
	EO	5,639,780	06/17/97	Lau et al.	514	419	05/22/95
	EP	5,643,933	07/01/97	Talley et al.	514	372	06/02/95
	EQ	5,677,318	10/14/97	Lau	514	361	07/11/96
	ER	5,691,374	11/25/97	Black et al.	514	473	05/18/95
	ES	5,698,584	12/16/97	Black et al.	514	462	10/25/96
	ET	5,710,140	01/20/98	Ducharme et al.	514	91	08/16/96
	EU	5,712,171	01/27/98	Zambias et al.	436	518	01/20/95
	EV	5,733,909	03/31/98	Black et al.	514	238.8	01/21/97
	EW	5,736,152	04/07/98	Dunn	424	426	10/27/95
	EX	5,756,083	05/26/98	Elliott	424	85.1	02/09/96
	EY	5,789,413	08/04/98	Black et al.	514	252.01	01/21/97
	EZ	5,817,700	10/06/98	Dube et al.	514	768	03/11/97
	FA	5,830,647	11/03/98	Eaton et al.	435	6	04/26/95
	FB	5,849,943	12/15/98	Atkinson et al.	560	8	04/07/97
	FC	5,861,419	01/19/99	Dube et al.	514	334	07/11/97
	FD	5,922,742	07/13/99	Black et al.	514	345	04/02/97
	FE	5,925,631	07/20/99	Black et al.	514	183	08/03/98

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))		Applicant Stephen R. Hanson	
		Filing Date June 25, 2003	Group Art Unit 1615

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	FF	5,932,546	08/03/99	Barrett et al.	514	4	10/04/96
	FG	5,969,451	10/19/99	Lyons et al.	310	90.5	12/13/96
	FH	6,008,232	12/28/99	Lakshmanan	514	324	08/04/98
	FI	6,103,740	08/15/00	Lakshmanan	514	324	08/04/98
	FJ	6,287,599	09/11/01	Burnside et al.	424	468	12/20/00
	FK	6,376,242	04/23/02	Hanson	435	334	09/21/00
	FL	6,388,073	05/14/02	Lang et al.	544	250	07/26/00
	FM	6,585,995	07/01/03	Hanson	424	424	09/21/00
	FN	6,653,500	11/25/03	Lang et al.	560	22	04/25/02
	FO	6,811,794	11/02/04	Burnside et al.	424	468	12/20/01

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	FP	0 253 310	10/26/94	EP				
	FQ	00/03746	01/27/00	PCT				
	FR	01/21163	03/29/01	PCT				
	FS	01/21259	03/29/01	PCT				
	FT	95/00501	01/05/95	PCT				
	FU	95/18799	07/13/95	PCT				
	FV	95/18972	07/13/95	PCT				
	FW	96/22529	07/25/96	PCT				
	FX	96/25498	08/22/96	PCT				
	FY	96/40750	12/19/96	PCT				
	FZ	97/28190	08/07/97	PCT				
	GA	99/10494	03/04/99	PCT				
	GB	99/47153	09/23/99	PCT				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 18852-002002/5202B		Application No. 10/603,401	
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>				Applicant Stephen R. Hanson			
				Filing Date June 25, 2003		Group Art Unit 1615	
(37 CFR §1.98(b))							
Examiner Initial	Desig. ID	Document					
	GC	Balan et al., "Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32—a 15 year review," Br. J. Radiol. 70:1169-73 (1997)					
	GD	Balduini et al., "Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders," Haematologica 77:40-43 (1992)					
	GE	Besselink et al., "The binding of human blood platelets to fibrinogen-, fibronectin-, and Arg-Gly-Asp-derivatized Sephadex G-10," J. Biomater. Sci. Polym. Edn. 7: 551-562 (1995)					
	GF	Broudy et al., "Thrombopoietin Stimulates Colony-Forming Init-Megakaryocyte Proliferation and Megakaryocyte Maturation Independently of Cytokines that Signal through the gp130 Receptor Subunit," Blood 8(6): 2026-2032 (1996)					
	GG	Chen et al., "Thrombospondin, a negative modulator of megakaryocytopoiesis," J Lab Clin Med 129:231-8 (1997)					
	GH	Cook et al., "The effects of two synthetic glycoprotein II b/III a antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active," Thromb Haemost 70:838-47 (1993)					
	GI	Cortelazzo et al., "Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis," N Engl J Med 332:1132-6 (1995)					
	GJ	Endres et al., "Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase," Proc Natl. Acad Sci USA, 95:8880-8885 (1998)					
	GK	Fleckenstein, A., "History of Calcium Antagonists," Circ. Res. 52(suppl1): I.3-I.16 (1983)					
	GL	Griffith et al., "Endothelin-derived relaxing factor," J. Am. Coll. Cardiol., 12:797-806 (1988)					
	GM	Jones et al., "Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide," J Med Chem 30:295-303 (1987)					
	GN	Ludwig et al., "Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders," Cancer Immunol Immunother 25:266-73 (1987)					
	GO	Mazzucconi et al., "Pipobroman therapy of essential thrombocythemia," Scand J Haematol 37:306-9 (1986)					
	GP	McCall et al., "Calcium entry blocking drugs: mechanisms of action experimental studies and clinical uses," Current Problems in Cardiology, 10: 1-80 (1985)					
	GQ	Meanwell et al., "Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains," J. Med. Chem 35: 2672-87 (1992)					
	GR	Moncada, S and E.A. Higgs, "Endogenous nitric oxide: physiology, pathology and clinical relevance," Eur J Clin Invest, 21:361-374(1991)					
	GS	Nagae, S. and Y. Hori, "Immune thrombocytopenia due to tranilast (Rizaben®): Detection of drug-dependent platelet-associated IgG," The Journal of Dermatology 25:706-709 (1998)					
	GT	Remington: The Science and Practice of Pharmacy, Nineteenth Edition, Volume II, Gennaro, A.R. (Ed.), Eaton, Pennsylvania: Mack Publishing Company, p.963 (1995)					
	GU	Van de Pette et al., "Primary thrombocythaemia treated with busulphan," British Journal of Haematology, 62:229-37 (1986)					
	GV	Wang et al., "Interferon-α directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1," Blood 96(6): 2093-2099 (2000)					
Examiner Signature				Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 18852-002002/5202B	Application No. 10/603,401
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))				Applicant Stephen R. Hanson	
				Filing Date June 25, 2003	Group Art Unit 1615
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
	GW	Wong et al., "Nonpeptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2- <i>n</i> -butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307)," J. Pharmacol. Exp. Ther. 247(1): 1-7 (1988)			
	GX	Yeager et al., "Effects of cyclophosphamide on murine bone marrow and splenic megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levels," J Cell Physiol 112:222-228 (1982)			

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	